Literature DB >> 2105272

Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines.

S J Cryz1, A S Cross, J C Sadoff, E Fürer.   

Abstract

Nontoxic, serologically reactive O polysaccharide was derived from Escherichia coli O18 lipopolysaccharide by acid hydrolysis, extraction with organic solvents, and gel filtration chromatography. Oxidized O polysaccharide was covalently coupled to either Pseudomonas aeruginosa toxin A or cholera toxin by using adipic acid dihydrazide as a spacer molecule in the presence of carbodiimide. The resulting conjugates were composed of approximately equal amounts of O polysaccharide and protein and were nontoxic and nonpyrogenic. Both conjugates engendered an immunoglobulin G antibody response in rabbits that recognized native O18 lipopolysaccharide. Such antibody was able to promote the uptake and killing of an E. coli O18 strain bearing the K1 capsule by human polymorphonuclear leukocytes. Immunoglobulin G isolated from the sera of rabbits immunized with either conjugate afforded protection against an E. coli O18 challenge when passively transferred to mice.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2105272      PMCID: PMC258465          DOI: 10.1128/iai.58.2.373-377.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  33 in total

Review 1.  Escherichia coli in extra-intestinal infections.

Authors:  I Orskov; F Orskov
Journal:  J Hyg (Lond)       Date:  1985-12

2.  Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use.

Authors:  R van Furth; P C Leijh; F Klein
Journal:  J Infect Dis       Date:  1984-04       Impact factor: 5.226

3.  The importance of the K1 capsule in invasive infections caused by Escherichia coli.

Authors:  A S Cross; P Gemski; J C Sadoff; F Orskov; I Orskov
Journal:  J Infect Dis       Date:  1984-02       Impact factor: 5.226

4.  Bacteremia in a long-term care facility. Spectrum and mortality.

Authors:  U Setia; I Serventi; P Lorenz
Journal:  Arch Intern Med       Date:  1984-08

5.  Preparation of a purified antigenic cholera toxoid.

Authors:  R Germanier; E Fürer; S Varallyay; T M Inderbitzin
Journal:  Infect Immun       Date:  1976-06       Impact factor: 3.441

6.  Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1.

Authors:  G Pluschke; M Achtman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

7.  Gram-negative septicemia in patients with hematologic malignancies.

Authors:  G Todeschini; F Vinante; F Benini; A Perini; F Pasini; G Cetto
Journal:  Eur J Cancer Clin Oncol       Date:  1984-03

8.  Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates.

Authors:  R Schneerson; J B Robbins; C Chu; A Sutton; W Vann; J C Vickers; W T London; B Curfman; M C Hardegree; J Shiloach
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

9.  Carrier-induced epitopic suppression, a major issue for future synthetic vaccines.

Authors:  M P Schutze; C Leclerc; M Jolivet; F Audibert; L Chedid
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

Review 10.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

Authors:  C S Bryan; K L Reynolds; E R Brenner
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  9 in total

1.  Outer membrane protein A, peptidoglycan-associated lipoprotein, and murein lipoprotein are released by Escherichia coli bacteria into serum.

Authors:  J Hellman; P M Loiselle; M M Tehan; J E Allaire; L A Boyle; J T Kurnick; D M Andrews; K Sik Kim; H S Warren
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

2.  Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis.

Authors:  Alan S Cross; Nancy Greenberg; Melissa Billington; Lei Zhang; Christopher DeFilippi; Ryan C May; Kanwaldeep K Bajwa
Journal:  Vaccine       Date:  2015-10-26       Impact factor: 3.641

3.  Endotoxin-mediated endothelial cell injury and activation: role of soluble CD14.

Authors:  M Arditi; J Zhou; R Dorio; G W Rong; S M Goyert; K S Kim
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

4.  Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates.

Authors:  X X Gu; C M Tsai
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

5.  Immunogenicity of Vibrio vulnificus capsular polysaccharides and polysaccharide-protein conjugates.

Authors:  J G Simonson; R J Siebeling
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

6.  The K1 capsule is the critical determinant in the development of Escherichia coli meningitis in the rat.

Authors:  K S Kim; H Itabashi; P Gemski; J Sadoff; R L Warren; A S Cross
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

7.  Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection.

Authors:  D E Schiff; C A Wass; S J Cryz; A S Cross; K S Kim
Journal:  Infect Immun       Date:  1993-03       Impact factor: 3.441

8.  Bactericidal/permeability-increasing protein protects vascular endothelial cells from lipopolysaccharide-induced activation and injury.

Authors:  M Arditi; J Zhou; S H Huang; P M Luckett; M N Marra; K S Kim
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

9.  Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli.

Authors:  Sohinee Sarkar; Glen C Ulett; Makrina Totsika; Minh-Duy Phan; Mark A Schembri
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.